CURRICULUM VITAE

NICOLE HANS, CNP, RN, MS

**** ******** **

Chesapeake, VA 23323

Phone: 757-***-****

Email: m71ryt@r.postjobfree.com

OBJECTIVE__________________________________________________________________________

To obtain a nurse practitioner position in which I can utilize my academic knowledge and clinical and work experiences to benefit the hiring practice.

EDUCATION

THE OHIO STATE UNIVERSITY, COLUMBUS, OHIO

Masters Degree in Adult Health and Illness Nurse Practitioner, December 2001

THE OHIO STATE UNIVERSITY, COLUMBUS, OHIO

Baccalaureate Degree in Nursing, June, 1997

LICENSES

Adult Nurse Practitioner, APRN, ANCC Board Certified

Virginia and Ohio Licensed Nurse Practitioner

Licensed Registered Nurse, The Virginia and Ohio Board of Nursing License Virginia and Ohio

Authorization to Prescribe

Completion of externship for prescriptive authority

Drug Enforcement Agency Licensure

Member of ACRP for research professional

2007 Completion of CITI Course in The Protection of Human Research Subjects

WORK EXPERIENCE

SENTARA MEDICAL GROUP, VIRGINIA BEACH, VIRGINIA

Adult Nurse Practitioner and Research Supervisor, July 2009-July 2012

provide follow-up patient care in the neurology division with a sub-specialty in

Movement Disorders

Sub-Investigator for clinical trials for Parkinson’s Disease patients

THE OHIO STATE UNIVERSITY MEDICAL CENTER, COLUMBUS, OHIO

Adult Nurse Practitioner and Research Coordinator/Supervisor, July 2006-June 2009

Provide emergency patient care and follow-up visits in the Movement Disorder

Division

Assists with clinical trials for Parkinson’s Disease patients.

CENTRAL OHIO PRIMARY CARE PHYSICIANS, COLUMBUS, OHIO

Adult Nurse Practitioner, July 2002-2006

Independently providing medical management to a wide variety of

patients in a family practice setting under indirect supervision of

three collaborating physicians; ability to diagnose, assess, plan,

treat, prescribe, and evaluate both acute and chronic illness.

MOUNT CARMEL WEST MEDICAL CENTER, COLUMBUS, OHIO

Staff Nurse, Medical Intensive Care Unit, June 2001-July 2002

Intensive monitoring of critically ill patients in a nine bed unit;

providing numerous life saving measures that include ventilator

support, intravenous drips, cardiac monitoring, and ACLS measures.

THE OHIO STATE UNIVERSITY MEDICAL CENTER, COLUMBUS, OHIO

Staff Nurse, Surgical Intensive Care Unit, June 1997-February 2001

Intensive monitoring of stable and unstable patients in a 44 bed unit;

supplying medications and intravenous fluids, detailed assessments

and a variety of procedures to a wide range of surgical patients including

burn, neuro, trauma, cardiac, transplant and general surgery patients.

THE OHIO STATE UNIVERISTY MEDICAL CENTER, COLUMBUS, OHIO

Student Nurse Associate, Dodd Hall, December 1995-June 1997

Rehabilitation unit-vital signs, weighing patients, hygiene care, EKG’s

phlebotomy, trach and G-tube care, suctioning, and charting.

CURRENT AND PAST RESEARCH EXPERIENCES

Sub-Investigator. A multi-centered, opened-label study to assess the long-

term safety of droxidopa in subjects with primary autonomic failure,

dopamine beta hydroxylase deficiency or non-diabetic neuropathy and

symptomatic neurogenic orthostatic hypotension. June 2011-present.

Sub-Investigator. A multi-center, open-label extension study to examine

safety and tolerability of ACP-103 in the treatment of psychosis in

Parkinson’s Disease. September 2010.

Sub-Investigator. A multicenter, double-blind, randomized, parallel-group,

placebo-controlled study to assess the clinical effect of droxidopa in the

treatment of symptomatic neurogenic orthostatic hypotension in patients with

parkinson's disease. May 2010-ongoing.

. Sub-Investigator. A Multi-Center, Placebo-Controlled, Double-Blind Trial

to examine the safety and efficacy of Pimavanserin in the Treatment of

Psychosis in Parkinson’s disease. May 2010-ongoing.

Sub-Investigator. Ipsen. A randomized, double-blind, placebo-controlled, study

of the efficacy and safety of Trimethobenzamide(Tigan) in the control of nausea and

vomiting during initiation and continued treatment with continuous apomorphine

(Apoken) in apomorphine-naïve subjects with Parkinson’s Disease suffering from

acute intermittent “off” episodes, with phased withdrawal of subjects from Tigan

to placebo. May 2010-ongoing.

Sub-Investigator. Schwarz Pharmaceuticals/SP921. A multicenter, randomized,

double-blind, placebo-controlled, 5-arm, parallel-group trial to assess rotigotine

transdermal system dose response in subjects with advanced-stage parkinson’s disease. February 2010-2012.

Sub-Investigator. Teva Pharmaceuticals. Andante: Add-On to Dopamine Agonists in

stage patients needing enhanced treatment efficacy. December 2010-ongoing.

Research Supervisor. Neurologix. Phase 2 Safety and Efficacy Study Evaluating

Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects with

Advanced Parkinson’s Disease. 2008-2009

Research Supervisor. Acadia Pharmaceuticals. ACP-103-015. A multi-centered,

open-labeled extension study of the safety and efficacy of ACP-103 in the treatment

of psychosis in Parkinson’s disease. 2008-2009

Research Supervisor. Acadia Pharmaceuticals. ACP-103-012. A multi-centered, double-blind, Placebo-controlled Trial to Examine the Safety and Efficacy of ACP-103

(pimavanserin tartrate) in the Treatment of Psychosis in Parkinson’s disease. 2008- 2009.

Research Supervisor. NIH/Parkinson’s Study Group/Weill-Medical College of

Cornell University. QE3. A randomized, double-blind, placebo-controlled trial of

Coenzyme Q10 in early Parkinson’s Disease. 2008-2009

Research Coordinator. Link Medicine Corp. LNK754. Phase-IIa. A Double-blind, placebo-controlled, randomized, multicentered, single-dose followed by multi-dosed study to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of LNK-754 (a farnesyl transferase inhibitor) inpatients with early Parkinson’s disease that

have no disability requiring dopaminergic therapy. 2008-2009.

Research Coordinator. Schwarz Pharmaceuticals. SP 921. A multi-centered,

Randomized, double-blind, placebo-controlled trial to assess rotigotine transdermal

system response in subjects with advanced-stage Parkinson’s disease. 2007-2009.

Research Coordinator. Parkinson’s Study Group/Boehringer Ingelheim. 248-662

PramiBID. A randomized, double-blind, active and placebo controlled efficacy study of pramipexole given 0.5mg and 0.75 mg bid in early Parkinson’s Disease. 2006-2008.

Research Coordinator. NIH/Parkinson’s Study Group. PROGENI. Parkinson’s

Research: Organized Genetics Initiative. Genetic study in siblings with Parkinson’s

Disease. 2004-2009.

Research Coordinator. Eisai. E2007-A001-303. A multi-centered, open-

labeled extension study of the efficacy, safety and tolerability of E2007 in levodopa

treated Parkinson’s disease patients with motor fluctuations. 2007-2008,

Research Coordinator. Eisai, E2007-A001-302. A multi-centered, randomized,

double-blind, placebo-controlled, parallel group study of the efficacy, safety, and

tolerability of E2007 in levodopa treated Parkinson’s disease patients with motor

fluctuations.2007-2008.

Research Coordinator. Novartis. QUEST-PD. An assessment of quality of life in

Advanced PD patients with end of dose wearing off on levodopa therapy switched to

Stalevo therapy. 2005-2007.

Research Coordinator. Schwarz Biosciences. A multicenter, multinational, double-

blind, randomized placebo-controlled trial of efficacy and safety of rotigotine, a dopamine

agonist delivered by CDA patch in patients with early Idiopatchic Parkinson’s disease.

2002-2009.

PRESENTATIONS______________________________________________________________________________

• Nonmotor Symptoms in Parkinson’s Disease. Sponsored by Teva Pharmaceuticals and Medtronics. Chesapeake, VA. July 2012.

• Nonmotor Symptoms in Parkinson’s Disease. Sponsored by Teva Pharmaceuticals. Norfolk, VA. April 2012.

Role of a Nurse Practitioner and Current Clinical Trials at Ohio State University.

Sponsored by Valeant Pharmaceuticals. Central Ohio Parkinson’s Society. Columbus,

Ohio April 26, 2008

Current Clinical Trials and Research Process. Roles of a research participant and

Principal Investigator. Wallace-Kettering Neuroscience Institute. Kettering, Ohio. March 28, 2009

Diagnosis and Treatment of Parkinson’s Disease. Sponsored by Teva Pharmaceuticals.

Columbus, Ohio. February 20, 2008.

Questions and Answers on Parkinson’s Disease and Current Clinical Trials at Ohio State

University. Ohio University Athens Support Group. October 14, 2008.

Questions and Answers on Parkinson’s Disease and Current Clinical Trials at Ohio State

University. Knightsbridge Forum Support Group. April 9, 2009.

Clinical Trials in Early Parkinson’s Disease for the Treatment Team, Virginia Beach,

VA. June 2011.

PUBLICATIONS _______________________________________________________________________________

Kieburtz, Karl, Pramipexole given twice per day has similar efficacy to an equivalent

Dosage given twice per day. Manuscript. PSG. October 2009.

HONORS

Phi Eta Sigma, honor society

Alpha Gamma Delta, honor society

Scarlet and Gray Scholarship

Golden Key National Honor Society

Senior Leader, The Ohio State University Soccer Club

REFERENCES

Provided upon request

Contact this candidate